Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Personalized ctDNA analysis for detection of residual disease and recurrence in surgically treated HNSCC patients

In a larger surgical HNSCC series from the LIONESS group, plasma ctDNA collected at least 14 days after surgery identified 91.3% of recurrences, with lead times up to 500 days.

NPJ Precis OncolPubMed 41634365DOI 10.1038/s41698-026-01309-0